Philip J Rosenfeld Selected Research

pegcetacoplan

1/2021	Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan.
1/2021	Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy.
1/2020	Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philip J Rosenfeld Research Topics

Disease

68	Macular Degeneration (Age-Related Maculopathy) 01/2022 - 10/2002
27	Choroidal Neovascularization 03/2022 - 08/2002
13	Geographic Atrophy 01/2022 - 09/2013
11	Diabetic Retinopathy (Retinopathy, Diabetic) 03/2022 - 01/2016
11	Macular Edema 01/2018 - 10/2003
9	Retinal Vein Occlusion 06/2021 - 07/2005
8	Disease Progression 01/2022 - 12/2011
8	Endophthalmitis (Ophthalmia) 01/2020 - 10/2006
7	Inflammation (Inflammations) 01/2021 - 06/2005
6	Atrophy 01/2021 - 01/2007
6	Hemorrhage 01/2020 - 04/2006
5	Telangiectasis (Telangiectasia) 01/2016 - 01/2009
4	Vascular Diseases (Vascular Disease) 06/2020 - 01/2016
4	Eye Diseases (Eye Disease) 02/2014 - 03/2008
3	Polypoidal Choroidal Vasculopathy 12/2021 - 01/2020
3	Retinal Detachment (Retinal Detachments) 08/2021 - 01/2017
3	Arterial Occlusive Diseases (Arterial Occlusive Disease) 06/2021 - 01/2017
3	Cataract (Cataracts) 07/2013 - 07/2005
2	Cicatrix (Scar) 03/2022 - 03/2011
2	Epiretinal Membrane (Epiretinal Membranes) 08/2021 - 01/2016
2	Infarction (Infarctions) 06/2020 - 10/2018
2	Retinal Neovascularization 01/2019 - 10/2016
2	Blindness (Hysterical Blindness) 01/2019 - 01/2017
2	Cysts 01/2018 - 07/2008
2	Central Serous Chorioretinopathy 01/2018 - 01/2009
2	Uveitis 01/2017 - 10/2006
2	Edema (Dropsy) 09/2013 - 10/2003
2	Histoplasmosis 09/2004 - 08/2002
2	Back Pain (Backache) 02/2004 - 10/2002
1	Pseudotumor Cerebri (Idiopathic Intracranial Hypertension) 01/2022
1	Vasculitis (Vasculitides) 12/2021
1	Ischemia 08/2021
1	Vitreous Detachment (Posterior Vitreous Detachment) 08/2021
1	Polyps 06/2021
1	Chorioretinitis 01/2021
1	Retinitis 01/2021
1	Rupture 01/2020
1	Hemangioblastoma 01/2020
1	Toxoplasmosis 01/2019
1	Neoplasms (Cancer) 01/2019
1	Giant Cell Arteritis (Horton Disease) 10/2018
1	Vision Disorders (Hemeralopia) 10/2018
1	Diarrhea 01/2017
1	Fatigue 01/2017
1	Ocular Hypertension (Glaucoma, Suspect) 01/2017
1	Nausea 01/2017
1	Muscle Cramp (Cramp) 01/2017
1	Stargardt Disease 01/2017
1	Lens Subluxation 01/2017
1	Anorexia 01/2017
1	Vitreous Hemorrhage 01/2017
1	Retinal Diseases 10/2016

Drug/Important Bio-Agent (IBA)

30	Retinaldehyde (Retinal)IBA 01/2022 - 04/2007
26	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2021 - 06/2005
20	Bevacizumab (Avastin)FDA Link 01/2019 - 06/2005
18	Ranibizumab (Lucentis)FDA Link 01/2020 - 04/2006
11	Verteporfin (Visudyne)FDA Link 01/2009 - 08/2002
9	Fluorescein (Funduscein)FDA LinkGeneric 01/2021 - 09/2004
6	afliberceptIBA 01/2018 - 05/2009
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2020
4	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 06/2020 - 10/2003
4	Indocyanine Green (Cardio-Green)FDA LinkGeneric 01/2020 - 11/2015
4	Retinal Pigments (Pigments, Visual)IBA 01/2020 - 09/2013
4	Pharmaceutical PreparationsIBA 10/2019 - 10/2010
4	Complement System Proteins (Complement)IBA 03/2014 - 10/2010
3	salicylhydroxamic acid (SHAM)IBA 01/2021 - 10/2006
3	pegcetacoplanIBA 01/2021 - 01/2020
2	Complement C3 (C3 Complement)IBA 01/2021 - 01/2020
2	KH902 fusion proteinIBA 01/2020 - 01/2019
2	Tyrosine Kinase InhibitorsIBA 01/2019 - 01/2017
2	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2018 - 01/2018
2	Monoclonal AntibodiesIBA 10/2018 - 10/2006
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2018 - 11/2011
2	ZeaxanthinsIBA 02/2014 - 07/2013
2	LuteinIBA 02/2014 - 07/2013
2	LipofuscinIBA 01/2014 - 10/2010
2	Endothelial Growth FactorsIBA 04/2011 - 05/2009
2	pegaptanib (Macugen)FDA Link 05/2009 - 07/2005
1	Acetazolamide (Diamox)FDA LinkGeneric 01/2022
1	Complement Inactivating AgentsIBA 01/2021
1	N-acetyltryptophanamide (NATA)IBA 01/2020
1	emixustatIBA 10/2018
1	Amino Acids FDA Link 10/2018
1	Amyloid (Amyloid Fibrils)IBA 10/2018
1	SDDSIBA 01/2017
1	hydroxide ionIBA 01/2017
1	Alanine Transaminase (SGPT)IBA 01/2017
1	RetinoidsIBA 01/2017
1	Transaminases (Aminotransferases)IBA 01/2017
1	A-factor (Streptomyces)IBA 10/2016

Therapy/Procedure

34	Therapeutics 01/2022 - 10/2002
13	Injections 01/2021 - 04/2006
13	Intravitreal Injections 01/2021 - 07/2005
10	Photochemotherapy (Photodynamic Therapy) 01/2009 - 08/2002
5	Light Coagulation 01/2022 - 06/2005
3	Lasers (Laser) 03/2022 - 06/2005
3	Aftercare (After-Treatment) 12/2021 - 06/2021
2	Traction 08/2021 - 01/2017
2	Retreatment 01/2020 - 04/2007
1	Vitrectomy 08/2021